April 28 – December 31, 2010This Full Year Report relates to Kancera’s first financial year, covering the period April 28 – December 31, 2010. There are thus no historical comparison figures. Kancera’s conditional acquisition of iNovacia AB took place...
Read MoreROR-1, target for the Kancera treatment for chronic lymphatic leukemia, has been identified on the surface of eight additional blood cancers. Accordingly, medical use of the Kancera candidate drug under development may be expanded within the frames of current...
Read MoreKancera AB (publ) announces that the acquisition of iNovacia AB has been implemented
Read MoreKancera AB (publ) ("Kancera") will be admitted to trading on OMX First North. The first trading day will be on Friday, 25 February 2011. The share's short name (ticker) is KAN.
Read MoreAs of 2 February 2011, Kancera AB’s future subsidiary iNovacia AB has sold its entire holding of 864,000 shares in Kancera AB at the price of SEK 7 per share. This means that the Kancera Group will receive around...
Read MoreKancera AB’s new share issue to the public ahead of listing on the NASDAQ OMX First North market was oversubscribed. The new share issue comprised 3,600,000 shares. The issue price was SEK 7 per share, which means that Kancera...
Read MoreKancera AB has in collaboration with Sprint Bioscience AB, Stockholm, solved the 3- dimensional crystal structure of a novel chemical class in complex with the target enzyme PFKFB3, by conducting experiments at the European Synchrotron Radiation Facility in Grenoble....
Read MoreKancera AB has discovered compounds that kill Chronic Lymphocytic Leukemia (CLL) 25 times more selectively than cytostatic drugs currently used for treating the disease.
Read MoreKancera AB (publ) is carrying out a new share issue, will be listed on First North, and is acquiring the research company iNovacia AB - thereby creating an international and highly competitive cancer drug company.
Read More